



March 2025



#### **Table of Contents and Introduction**

Introduction	2
Key Ecosystem Characteristics	4
Ecosystem Mindmap	5
Platform Overview	6
History and Main Principles	12
Conclusions	18
Policy and Governance	21

#### Introduction

The Longevity Ecosystem in Geneva, supported by Deep Knowledge Group (DKG), is playing a key role in fostering collaboration and accelerating technological advancements in the region.

Serving as a vital platform, it brings together a diverse network of professionals from research, industry, finance, and other fields to drive the rapid evolution of the longevity sector.

This dynamic hub not only showcases the cutting-edge innovations emerging from Geneva but also creates a collaborative environment where stakeholders can exchange insights, form partnerships, and align strategies for mutual growth.

#### Introduction

At its core, the Longevity Ecosystem platform highlights the vital intersection between biomedicine, DeepTech, and AI, propelling Geneva as a central hub for the global Longevity Industry. The region's focus on integrating advanced technologies such as AI, blockchain, and robotics into longevity research and healthcare applications underscores its leading role in this emerging field. By leveraging DKG's expertise in data analytics, market intelligence, and industry benchmarking, the platform offers a powerful tool for understanding the complexities and vast potential of the longevity sector.

The Geneva-based ecosystem is strategically positioned to harness the synergies between diverse technologies. These include innovations in health data, digital avatars, and biomarkers of human longevity, as well as cross-sector collaboration between biotech, financial institutions, and governments. This interconnected approach is essential for advancing longevity science, optimizing healthspan, and creating new financial systems that will support the longevity economy. By providing a comprehensive analytical framework, DKG facilitates investment opportunities, policy development, and R&D in precision medicine, genomics, and regenerative therapies.

As the Longevity Ecosystem in Geneva continues to expand, it offers unique opportunities for individuals and organizations to contribute to the global longevity movement. Researchers, entrepreneurs, and investors alike can explore groundbreaking developments in areas such as gene therapy, regenerative medicine, and age-tech solutions. By actively engaging with the ecosystem, stakeholders will be at the forefront of shaping a healthier, longer-lived future for generations to come. This collaboration fosters the creation of innovative solutions, setting the stage for a global transformation in longevity, driven by technology, knowledge, and foresight.

Explore the dynamic growth and innovation that the Geneva Longevity Ecosystem offers, and discover how your participation can contribute to shaping the future of longevity and technological advancement.

## **Key Ecosystem Characteristics**

#### **Key Ecosystem Characteristics**

#### Key Leaders and Innovators in Geneva's Longevity Ecosystem

Geneva's longevity ecosystem is home to over 425 leaders and 345 companies the forefront of alobal research and development. With key professionals driving the future of longevity, the city is positioned as a hub for innovation, combining expertise from AI. biotechnology, and health tech to advance the field.

# Strategic Opportunities for Investors in Longevity

Investors have unique opportunities within the Geneva ecosystem, with investors actively seeking high-impact ventures in longevity. The growing integration of Al. biotech. precision and health significant promises returns in emerging sectors like personalized medicine.

#### Expanding the Longevity Industry's Global Reach


The Ecosystem connects global leaders in research and business, fostering collaboration across multiple sectors including HealthTech, Biotech, and This integration enables innovation. creating opportunities for breakthroughs that can impact industries far beyond healthcare.

# Al's Role in Accelerating Longevity Innovations

Al and Big Data analytics are transforming the landscape of longevity innovation in Geneva. By leveraging cutting-edge technologies, Al is accelerating R&D, improving personalized treatments, and reshaping clinical trials.

# Bridging Cross-Sector Collaboration for Breakthrough Solutions

Cross-sector collaboration is a kev driver in advancing the longevity industry. Partnerships between innovators. tech healthcare professionals, and investors, enable the rapid development and scaling of formative solutions in healthspan extension.



Source: Longevity Ecosystem in Geneva

**Platform Overview** 


#### **Platform Overview**

## **Longevity Ecosystem in Geneva**

Beta Version Powered by Deep Knowledge Group with the support of Delta Finance


Supported by Deep Knowledge Group, Longevity Ecosystem in Geneva encourages business collaboration and knowledge exchange within the region. The platform showcases leading professionals from across Geneva who are driving innovation and spearheading a transformative wave in the technology field. Tailored to cater to researchers, industry experts, investors, and other stakeholders, the Longevity Ecosystem in Geneva platform offers a comprehensive perspective on the ever-evolving landscape of technology in the region. Explore the diverse realms of tech innovation and discover the limitless possibilities that the Geneva Longevity Ecosystem has to offer.





Source: Longevity Ecosystem in Geneva

#### **Platform Overview**




The Geomap slide visually represents the interconnectedness of Geneva's longevity ecosystem, highlighting key players, such as biotech companies, research hubs, investors, and strategic partnerships. It showcases the city's growing role as a global center for longevity innovation.

The map emphasizes the collaboration between AI, biotech, and healthcare sectors, driving breakthroughs in aging research and personalized medicine.

By mapping out the various nodes and their relationships, the slide illustrates how Geneva fosters a dynamic environment for cross-sector growth, attracting international talent and investment, and positioning itself at the forefront of the longevity industry.

Source: Longevity Ecosystem in Geneva



Source: Longevity Ecosystem in Geneva

## **Switzerland Leaders**



www.swiss-ecosystem.tech/leaders

## Longevity Ecosystem in Geneva Knowledge Hub (Beta Version)


Scientific & IT Resources >	Education & Collaboration >	Media & Trends >	Rankings & Top Leads >	Online Communities >
20 Tech Books	25 Conferences in Geneva	40 Geneva Leaders Interviews	345 Tech Companies	20 Linkedin
20 Tech Journals	20 Workshops in Geneva	25 Podcasts by Geneva experts	425 Tech Leaders	20 Facebook
200 Tech Articles	20 Geneva Certification Programmes	50 Geneva Blogs	150 Investors	10 Reddit
15 Tech Benchmarks	20 Geneva University Programs	500 News in Geneva	500 Startups	10 GitHub
40 Tech Reports	20 Online Courses in Geneva	100 Social Networks in Geneva	30 Hubs	10 Quora
40 Tech Databases	20 Lectures by Geneva Leaders	10 Market Trends in Geneva	160 Geneva Cities	10 Twitter
10 Tech Software	20 Geneva Research Projects	10 Geneva Diversity Trends	30 Consulting Services	10 Discord
20 Tech Models	20 Scholarship Funds in Geneva	10 Women Leading the Field	10 Geneva Universities	10 Other Forums

Source: Longevity Ecosystem in Geneva

History and Main Principles

### **Opportunities and Challenges**

Geneva's longevity ecosystem offers numerous benefits, including cutting-edge innovation, strong investment, and global collaboration. However, challenges remain, such as regulatory hurdles and funding gaps in early-stage ventures. Balancing technological advancement with ethical concerns and ensuring accessibility will be key to long-term success.



## **Timeline of Recent Developments**











2024 Q1

2024 Q2 °

2024 Q3

2023 Q4

2023 Q2

2023 Q3

#### Gene Therapy Breakthrough Achieved

New funding from private and public sectors is allocated to develop aging biomarkers and personalized longevity treatments.

#### Al-Powered Drug Discovery

A significant breakthrough in gene therapy offers hope in slowing aging, marking a milestone in regenerative medicine research.

# **Longevity Investment Surge**

Longevity investment in Switzerland peaks, drawing major international investors to fund cutting-edge research in longevity and aging technologies.

#### International Longevity Summit Hosted

Al advancements accelerate drug discovery, enhancing clinical trial efficiency and leading to faster development of longevity treatments.

# Longevity Research Funding Secured

Research into longevity biomarkers gains momentum as investors look to fund tools that track and reverse age-related diseases.

#### **Global Summit**

Geneva hosts a global summit on longevity, discussing cross-sector partnerships and new technologies advancing aging research and solutions.

### What Makes a Longevity Valley?

Financial Institutions and FinTech Companies: Switzerland's global reputation as a financial innovator is reflected in its role as a Longevity Financial Hub. The country's financial sector, with a strong presence of progressive asset management firms, investment banks, pension funds, and insurance companies, is pioneering new business models using Al for enhanced analytics, thereby accelerating the development of the Longevity Financial Industry.

Biotechnology and Pharmaceutical Companies: Central to the Swiss Longevity Valley are its biotech and pharmaceutical clusters, particularly noted in Basel, part of the BioValley, which spans three countries. This hub is characterized by a high concentration of companies, a wealth of skills and experience in the life sciences, and a world-class research base, making it a global life-science hub.


Research Institutions and Universities: Switzerland boasts a robust research environment with institutions dedicated to geroscience, precision medicine, and digital health. These academic hubs foster an atmosphere of innovation, supporting the translation of scientific discoveries into practical applications for the Longevity Industry.


Policy and Government Organizations: The Swiss political system's responsiveness to demographic changes underscores its role as a Longevity Policy and Government Hub. The government's support for R&D, coupled with initiatives to develop a comprehensive healthcare system, positions Switzerland to leverage aging as an opportunity rather than a challenge.


Non-Profit Organizations and Think Tanks: Non-profit organizations and think tanks are instrumental in transforming Switzerland into a world-leading Longevity Valley. These organizations facilitate dialogue and collaboration across sectors, promoting Switzerland as an epicenter for the Longevity Industry.

Precision Clinics and Healthcare Facilities: The development of precision clinics and healthcare facilities specializing in personalized and preventive medicine is a critical component of Switzerland's Longevity ecosystem. These institutions leverage the latest in medical technology and research to provide care that is tailored to the individual, contributing to the nation's high life expectancy and quality of life.

## **Swiss Personalized Health Network (SPHN)**







**Key Conclusions: The Road Ahead** 

## **History, Current State and The Road Ahead**

#### **History, Current State and The Road Ahead**

#### **History**

Geneva has long been a center for scientific innovation, with a strong foundation in biotech, pharmaceuticals, healthcare research. The city's longevity ecosystem began taking shape early 2000s. fueled advancements in regenerative medicine and Al-driven healthcare solutions. By the 2010s, Geneva became a hub for longevity research, attracting investors, scientists, and biotech startups. Organizations like Knowledge Group helped Deep accelerate growth by providing industry insights, investment opportunities, and technology-driven research collaborations. The emergence of precision medicine and Al-enhanced biomarker tracking set the stage for Geneva to become a global leader in longevity sciences.

#### **Current State**

Today. Geneva hosts 345 over longevity-focused companies, 150 investors, and 75 research hubs, forming a dynamic ecosystem. Al and Big Data analytics play a key role in accelerating drug discovery, personalized treatments, and biomarker research. The city is a hub for cross-sector collaboration, integrating biotech, health tech, and Al-driven innovation. Maior longevity summits and conferences attract global experts, further solidifying Geneva's position as a leader in the field. With and increasing investments strong government support, the region is shaping the future of longevity science, aiming to extend healthspan and improve quality of life through groundbreaking research.

#### The Road Ahead

Geneva's longevity ecosystem is poised for exponential growth, with Al-driven healthcare and personalized medicine leading the charge. Future developments will focus on integrating biomarker-based diagnostics, regenerative medicine. Al-enhanced and longevity interventions. Strategic partnerships between biotech firms, research institutions, and investors will drive innovation and scalability. introduction The of longevity-focused investment funds and policy frameworks will further strengthen the industry's foundation. By 2030, Geneva is expected to be a major global hub for longevity research, contributing to breakthroughs in aging science, disease prevention, and healthspan extension. The city's unique ecosystem will continue to redefine the future of human longevity.

### **Key Takeaways**



**Geneva's longevity ecosystem is thriving**, supported by cutting-edge AI technologies, biotech innovation, and global collaborations. This unique synergy fosters rapid advancements in aging science, precision medicine, and regenerative treatments, positioning Geneva as a global leader in longevity research and investment opportunities.



Al-driven solutions are revolutionizing longevity research in Geneva. From drug discovery to biomarker tracking, Al is accelerating clinical trials and personalizing treatments. This technological integration is poised to significantly extend healthspan and improve quality of life, driving long-term growth in the sector.



With strong investment and collaboration, Geneva's longevity ecosystem is attracting global attention. The city is becoming a key destination for longevity-focused startups, researchers, and investors, creating an environment ripe for breakthroughs in aging science, regenerative medicine, and Al-powered healthcare solutions.

#### contact@swiss-ecosystem.tech

